PH12018502296B1 - Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof - Google Patents

Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Info

Publication number
PH12018502296B1
PH12018502296B1 PH12018502296A PH12018502296A PH12018502296B1 PH 12018502296 B1 PH12018502296 B1 PH 12018502296B1 PH 12018502296 A PH12018502296 A PH 12018502296A PH 12018502296 A PH12018502296 A PH 12018502296A PH 12018502296 B1 PH12018502296 B1 PH 12018502296B1
Authority
PH
Philippines
Prior art keywords
benzoimidazol
diethylamino
acrylamide
hydroxy
butyl
Prior art date
Application number
PH12018502296A
Other languages
English (en)
Other versions
PH12018502296A1 (en
Inventor
David Duncan
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of PH12018502296A1 publication Critical patent/PH12018502296A1/en
Publication of PH12018502296B1 publication Critical patent/PH12018502296B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12018502296A 2016-05-02 2018-10-29 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof PH12018502296B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02
PCT/US2017/030414 WO2017192451A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Publications (2)

Publication Number Publication Date
PH12018502296A1 PH12018502296A1 (en) 2019-07-08
PH12018502296B1 true PH12018502296B1 (en) 2022-04-06

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018502296A PH12018502296B1 (en) 2016-05-02 2018-10-29 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Country Status (20)

Country Link
US (2) US10626092B2 (enExample)
EP (2) EP3939966A1 (enExample)
JP (1) JP2019514905A (enExample)
KR (1) KR20190005904A (enExample)
CN (1) CN109414425A (enExample)
AR (1) AR108257A1 (enExample)
AU (1) AU2017261218A1 (enExample)
BR (1) BR112018072439A2 (enExample)
CA (1) CA3022011A1 (enExample)
CL (1) CL2018003109A1 (enExample)
CO (1) CO2018012941A2 (enExample)
EA (1) EA201892341A1 (enExample)
ES (1) ES2886495T3 (enExample)
IL (1) IL262578A (enExample)
MA (1) MA44880A (enExample)
MX (1) MX382095B (enExample)
PH (1) PH12018502296B1 (enExample)
SG (1) SG11201809471UA (enExample)
TW (1) TW201741286A (enExample)
WO (1) WO2017192451A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157742A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
WO2019126282A1 (en) 2017-12-19 2019-06-27 Assia Chemical Industries Ltd. Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
US20230159468A1 (en) 2020-04-22 2023-05-25 Macfarlan Smith Limited Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
CA2135173A1 (en) 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
CN1358094A (zh) 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Mek阻害剤を用いる慢性疼痛の治療方法
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2473505A1 (en) 2002-02-07 2003-08-14 Ellen M. Leahy Novel bicyclic hydroxamates as inhibitors of histone deacetylase
CA2478534A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
CA2478374C (en) 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
AU2003231359B2 (en) 2002-04-16 2009-04-30 Teijin Limited Piperidine derivatives having CCR3 antagonism
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
MY142589A (en) 2003-09-22 2010-12-15 S Bio Pte Ltd Benzimidazole derivatives : preparation and pharmaceutical applications
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
CA2540459C (en) * 2005-09-08 2014-02-18 S*Bio Pte Ltd Benzimidazole compounds and uses in treating proliferative disorders
PL1937650T3 (pl) * 2005-09-08 2011-11-30 Mei Pharma Inc Związki heterocykliczne
EP2131840B1 (en) 2007-03-07 2018-10-17 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
EP3662911A1 (en) 2012-10-30 2020-06-10 MEI Pharma, Inc. Combination of azacitidine and pracinostat to treat myelodysplastic syndrome (mds)

Also Published As

Publication number Publication date
US20200317621A1 (en) 2020-10-08
EA201892341A1 (ru) 2019-05-31
CN109414425A (zh) 2019-03-01
BR112018072439A2 (pt) 2019-02-19
EP3452035A1 (en) 2019-03-13
ES2886495T3 (es) 2021-12-20
KR20190005904A (ko) 2019-01-16
JP2019514905A (ja) 2019-06-06
TW201741286A (zh) 2017-12-01
AR108257A1 (es) 2018-08-01
WO2017192451A1 (en) 2017-11-09
MX2018013349A (es) 2019-02-20
SG11201809471UA (en) 2018-11-29
PH12018502296A1 (en) 2019-07-08
EP3452035A4 (en) 2019-09-25
EP3939966A1 (en) 2022-01-19
AU2017261218A1 (en) 2018-11-29
IL262578A (en) 2018-12-31
US20190152923A1 (en) 2019-05-23
CA3022011A1 (en) 2017-11-09
CO2018012941A2 (es) 2018-12-28
MX382095B (es) 2025-03-13
MA44880A (fr) 2021-03-17
CL2018003109A1 (es) 2019-04-26
US10626092B2 (en) 2020-04-21
EP3452035B1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
EP3481402A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
MX2018003284A (es) Compuestos antifungicos y procesos para hacerlos.
PH12016501941A1 (en) Use of heterocyclic compounds for controlling nematodes
PH12017500920A1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139
PH12018502296B1 (en) Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof
TWI799397B (zh) 用於治療高血壓之組合物
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
PH12016501613A1 (en) Pyrazines modulators of gpr6
IL259297A (en) Heterocyclic compounds for the treatment of disease
HUE067197T2 (hu) Készítmények patogének által okozott fertõzések kezelésére
WO2015001541A3 (en) Pharmaceutical film composition
PT3823655T (pt) Composições para o tratamento da vulvodínia
MY188420A (en) Crystalline forms of (s)-afoxolaner
EP3655379A4 (en) Methods for preparing bis-tetrahydroisoquinoline-containing compounds
GB201500867D0 (en) Compound or mixture of compounds for the treatment of neurodegenerative diseases or oxidative stress injuries
NZ735249A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer’s disease
WO2015170340A3 (en) Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
HK40070316B (zh) 用於治疗疾病的杂环化合物
SMT202400184T1 (it) Composizioni per il trattamento di infezioni patogene
HK40015207A (en) Compositions for the treatment of hypertension